Dutasteride and gynaecomastia are closely linked concerns for men prescribed this medication in the UK. Dutasteride, a dual 5-alpha reductase inhibitor licensed for benign prostatic hyperplasia (BPH), works by suppressing dihydrotestosterone (DHT), which can shift the balance between androgens and oestrogens in the body. This hormonal change may stimulate breast glandular tissue in some men, leading to tenderness, swelling, or enlargement. Understanding the mechanism, frequency, and risk factors — as well as knowing when to seek medical advice — is essential for anyone taking or considering dutasteride.

How Dutasteride Works and Its Effect on Hormones

Dutasteride blocks both type 1 and type 2 5-alpha reductase isoforms, reducing DHT by approximately 90% and raising the oestrogen-to-androgen ratio, which can stimulate breast glandular tissue.

Dutasteride is a dual 5-alpha reductase inhibitor, meaning it blocks both type 1 and type 2 isoforms of the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). It is licensed in the UK for the treatment of benign prostatic hyperplasia (BPH) and is sometimes used off-label for androgenetic alopecia (male pattern hair loss). By substantially reducing circulating DHT levels — by approximately 90% overall, and up to around 94% at steady state according to the UK Summary of Product Characteristics (SmPC) for Avodart — dutasteride alters the hormonal environment within the body.

Not sure if this is normal? Chat with one of our pharmacists →

This hormonal shift has downstream consequences. When DHT is suppressed, serum testosterone levels may rise modestly, though typically remaining within the normal range as noted in the SmPC. Testosterone can itself be aromatised (converted) into oestradiol, a form of oestrogen, by the enzyme aromatase found in adipose (fat) tissue and other sites. The resulting relative increase in the oestrogen-to-androgen ratio is the key mechanism thought to underlie several of dutasteride's hormonal side effects, including changes to breast tissue.

It is important to understand that dutasteride does not directly introduce oestrogen into the body. Rather, it shifts the balance between androgens and oestrogens in a way that, in some individuals, may stimulate breast glandular tissue. This mechanism is well-recognised across the class of 5-alpha reductase inhibitors and is not unique to dutasteride alone.

Gynaecomastia as a Recognised Side Effect of Dutasteride

Gynaecomastia is a recognised, listed adverse effect of dutasteride in the Avodart SmPC, acknowledged by both the EMA and MHRA, typically presenting as breast tenderness, palpable glandular tissue, or swelling.

Yes — gynaecomastia (the development of enlarged or tender breast tissue in males) is a recognised side effect of dutasteride. It is listed in the SmPC for Avodart (the branded form of dutasteride) and is acknowledged by both the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) as an adverse reaction associated with this medication.

Gynaecomastia in this context typically presents as:

• Breast tenderness or sensitivity, often the earliest symptom

• Palpable glandular tissue beneath one or both nipples

• Breast enlargement or swelling, which may be unilateral or bilateral

These changes occur because the altered androgen-to-oestrogen ratio stimulates oestrogen receptors in breast glandular tissue. It is worth noting that true gynaecomastia involves actual glandular proliferation, as distinct from pseudogynaecomastia, which refers to fatty tissue accumulation without glandular involvement. Dutasteride is associated with the former.

The condition is generally benign; however, any new breast lump or change should always be assessed promptly by a healthcare professional to rule out other causes. Importantly, nipple discharge in men — particularly if blood-stained — is not a typical feature of gynaecomastia and should be treated as a red flag requiring urgent assessment via the NHS suspected cancer (two-week wait) pathway (NICE NG12). The MHRA has also highlighted that rare cases of male breast cancer have been reported in association with 5-alpha reductase inhibitors; whilst a causal relationship has not been established, this underlines the importance of promptly evaluating any breast changes in men taking these medicines.

How Common Is Gynaecomastia With Dutasteride?

Breast disorders are classified as common adverse effects of dutasteride, occurring in approximately 1–2% of users in pivotal BPH trials, with longer treatment duration associated with greater cumulative risk.

According to the Avodart SmPC and EMA EPAR, breast disorders — including breast tenderness and breast enlargement — are classified as common adverse effects of dutasteride, meaning they occur in approximately 1 in 100 to 1 in 10 users. In the pivotal clinical trials for BPH, breast-related adverse events were reported in roughly 1–2% of participants taking dutasteride, compared with lower rates in placebo groups, as documented in the SmPC.

The duration of treatment appears to be relevant — longer-term use is associated with a greater cumulative likelihood of developing breast changes, though the precise magnitude of this duration-related risk increase is not well quantified in available data.

Comparison with finasteride (a type 2-only 5-alpha reductase inhibitor) is sometimes made in clinical practice. Because dutasteride inhibits both isoforms and achieves more profound DHT suppression, some clinicians consider it plausible that hormonal side effects may be marginally more pronounced; however, robust head-to-head comparative data are limited, and this should not be presented as established fact. NICE guideline NG123 on lower urinary tract symptoms in men recommends that patients prescribed 5-alpha reductase inhibitors should be counselled about potential side effects, including breast changes, before treatment begins. Overall, while gynaecomastia is not an inevitable consequence of taking dutasteride, it is sufficiently common that patients should be informed about this possibility prior to commencing treatment.

Risk Factors That May Increase Your Likelihood

Obesity, older age, concurrent gynaecomastia-associated medications, pre-existing hormonal conditions, chronic alcohol use, and liver disease may all increase the likelihood of developing gynaecomastia with dutasteride.

Not everyone who takes dutasteride will develop gynaecomastia. Several individual factors may increase susceptibility, and understanding these can help patients and clinicians make more informed treatment decisions.

Factors that may increase risk include:

• Higher body weight or obesity: Greater adipose tissue mass means more aromatase activity, leading to increased conversion of testosterone to oestradiol, amplifying the hormonal imbalance caused by dutasteride.

• Older age: Testosterone levels naturally decline with age, meaning the relative oestrogen excess created by DHT suppression may be more pronounced in older men.

• Concurrent medications: Certain drugs are independently associated with gynaecomastia and may act additively with dutasteride. Well-established associations include spironolactone, antiandrogens, some antipsychotics (notably risperidone), certain antiretrovirals (such as efavirenz), ketoconazole, anabolic steroids, and H2 receptor antagonists — particularly cimetidine. Calcium channel blockers (primarily verapamil and diltiazem) have been implicated rarely. Patients should mention all current medicines, including over-the-counter products and supplements, to their prescribing clinician.

• Pre-existing hormonal conditions: Conditions such as hypogonadism, hyperthyroidism, or liver disease can alter baseline hormone metabolism and increase vulnerability.

• Alcohol use: Chronic alcohol consumption can impair hepatic testosterone metabolism and raise oestrogen levels.

• Genetic factors: Individual variation in androgen receptor sensitivity and aromatase activity may theoretically influence susceptibility, though the evidence base for this in clinical practice remains limited.

It is also important to note that gynaecomastia can arise from causes unrelated to dutasteride — including testicular tumours, hCG-secreting tumours, and other endocrine disorders — and these should be considered and excluded during clinical assessment, particularly if breast changes are atypical or accompanied by other symptoms.

Patients with several of these risk factors should discuss them openly with their prescribing clinician before starting dutasteride, so that an individualised risk-benefit assessment can be made and appropriate monitoring arranged.

What to Do If You Notice Breast Changes While Taking Dutasteride

Do not stop dutasteride abruptly; book a GP appointment promptly to assess breast changes, and seek urgent review if red flag features such as a hard irregular lump or blood-stained nipple discharge are present.

If you are taking dutasteride and notice any changes in your breast tissue — such as tenderness, swelling, or a lump — it is important not to ignore these symptoms. Whilst dutasteride-related gynaecomastia is generally benign, breast changes should always be evaluated promptly by a healthcare professional.

Practical steps to take:

• Do not stop dutasteride abruptly without speaking to your GP or prescribing clinician first. Stopping treatment suddenly may affect your underlying condition (e.g., BPH symptoms may return).

• Book a GP appointment to discuss the changes. Your GP will take a history, examine the breast tissue, and determine whether further investigation is needed.

• Be prepared to describe when the changes started, whether they are painful, and whether they are getting worse.

• Mention all other medications you are taking, including over-the-counter products and supplements, as these may contribute.

If the cause of breast changes is uncertain, your GP may arrange initial investigations — which can include blood tests (liver function, thyroid function, testosterone, LH, FSH, oestradiol, and hCG) and a testicular examination — to help identify or exclude other causes.

If dutasteride is confirmed as the likely cause, your GP may discuss the options of stopping dutasteride, switching to an alternative treatment (for example, an alpha-blocker for BPH), or watchful waiting if symptoms are mild — depending on the severity of symptoms, your underlying condition, and your preferences. There is no licensed lower dose of dutasteride for BPH, so a dose reduction is not an appropriate management option.

Gynaecomastia may partially or fully resolve after stopping the medication, though this is not guaranteed — particularly if the condition has been present for a prolonged period, as fibrotic changes in breast tissue can become permanent over time.

Seek urgent assessment if you notice a hard or irregular unilateral breast lump, nipple retraction, blood-stained nipple discharge, or swollen lymph nodes in the armpit. These are red flag features that warrant urgent referral via the NHS suspected cancer (two-week wait) pathway in line with NICE guideline NG12. Otherwise, your GP may arrange routine breast clinic referral or imaging (ultrasound or mammography) as appropriate.

MHRA Guidance and When to Speak to Your GP

The MHRA recognises gynaecomastia as a known dutasteride adverse effect and advises prompt GP review for any breast changes; red flag features require urgent referral under the NICE NG12 two-week wait pathway.

The MHRA, which regulates medicines in the UK, has acknowledged gynaecomastia as a known adverse effect of dutasteride through its inclusion in the product's official labelling. The MHRA has also issued guidance highlighting that rare cases of male breast cancer have been reported with 5-alpha reductase inhibitors; whilst causality has not been confirmed, this reinforces the importance of promptly reporting and evaluating any breast changes in men taking these medicines.

Patients and healthcare professionals are encouraged to report suspected adverse drug reactions — including gynaecomastia — via the Yellow Card scheme (available at yellowcard.mhra.gov.uk or via the Yellow Card app), which helps the MHRA monitor the ongoing safety profile of medicines in clinical use.

NICE guideline NG123 on the management of lower urinary tract symptoms in men recommends that patients prescribed 5-alpha reductase inhibitors such as dutasteride should be counselled about potential side effects, including sexual dysfunction and breast changes, before treatment begins. Shared decision-making is central to this guidance, ensuring patients are fully informed.

You should contact your GP promptly if you experience:

• Any new breast lump, swelling, or asymmetry

• Persistent breast pain or tenderness lasting more than a few weeks

• Breast changes that are worsening over time

• Any breast change accompanied by systemic symptoms such as unexplained weight loss or fatigue

Seek urgent assessment if you notice nipple discharge (especially if blood-stained), a hard or irregular unilateral lump, nipple retraction, or swollen axillary lymph nodes — these features require urgent referral under the NHS two-week wait suspected cancer pathway (NICE NG12).

Whilst dutasteride-associated gynaecomastia is rarely serious, it can cause significant discomfort and psychological distress. Open communication with your GP ensures that the most appropriate management plan — whether that involves continuing, switching, or stopping treatment — is tailored to your individual circumstances. Never hesitate to raise concerns about medication side effects; doing so is an important part of safe, patient-centred care.

Frequently Asked Questions